Victor E Velculescu

Professor

1993 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Victor E Velculescu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Neoplasms Medicine & Life Sciences
Mutation Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences
Genes Medicine & Life Sciences
Genome Medicine & Life Sciences
Pancreatic Neoplasms Medicine & Life Sciences
DNA Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1993 2019

Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology

the IBCD-Faculty, Jun 1 2019, In : European Journal of Cancer. 114, p. 128-136 9 p.

Research output: Contribution to journalArticle

Precision Medicine
Neoplasms
Delivery of Health Care
Tumor Biomarkers
Industry

Circulating tumor DNA as a clinical test in resected pancreatic cancer

Groot, V. P., Mosier, S., Javed, A. A., Teinor, J. A., Gemenetzis, G., Ding, D., Haley, L. M., Yu, J., Burkhart, R. A., Hasanain, A., Debeljak, M., Kamiyama, H., Narang, A., Laheru, D. A., Zheng, L., Lin, M. T., Gocke, C. D., Fishman, E. K., Hruban, R. H., Goggins, M. G. & 7 others, Quintus Molenaar, I., Cameron, J. L., Weiss, M. J., Velculescu, V. E., He, J., Wolfgang, C. L. & Eshleman, J. R., Aug 15 2019, In : Clinical Cancer Research. 25, 16, p. 4973-4984 12 p.

Research output: Contribution to journalArticle

Pancreatic Neoplasms
DNA
Neoplasms
Adenocarcinoma
Recurrence

Combined MEK and Bcl-2/X L inhibition is effective in high-grade serous ovarian cancer patient–derived xenograft models and BIM levels are predictive of responsiveness

Iavarone, C., Zervantonakis, I. K., Selfors, L. M., Palakurthi, S., Liu, J. F., Drapkin, R., Matulonis, U. A., Hallberg, D., Velculescu, V. E., Leverson, J. D., Sampath, D., Mills, G. B. & Brugge, J. S., Mar 1 2019, In : Molecular cancer therapeutics. 18, 3, p. 642-655 14 p.

Research output: Contribution to journalArticle

Mitogen-Activated Protein Kinase Kinases
Heterografts
Ovarian Neoplasms
MAP Kinase Signaling System
Drug Combinations
Consultants
Oncogenes
T-Lymphocytes
Conflict of Interest
Organized Financing

Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer

Anagnostou, V., Forde, P. M., White, J. R., Niknafs, N., Hruban, C., Naidoo, J., Marrone, K., Ashok Sivakumar, I. K., Bruhm, D. C., Rosner, S., Phallen, J., Leal, A., Adleff, V., Smith, K. N., Cottrell, T. R., Rhymee, L., Palsgrove, D. N., Hann, C. L., Levy, B., Feliciano, J. & 16 others, Georgiades, C., Verde, F., Illei, P., Li, Q. K., Gabrielson, E., Brock, M. V., Isbell, J. M., Sauter, J. L., Taube, J., Scharpf, R. B., Karchin, R., Pardoll, D. M., Chaft, J. E., Hellmann, M. D., Brahmer, J. R. & Velculescu, V. E., Jan 1 2019, In : Cancer Research. 79, 6, p. 1214-1225 12 p.

Research output: Contribution to journalArticle

Open Access
Non-Small Cell Lung Carcinoma
DNA
Neoplasms
Therapeutics
Confidence Intervals